Comparative Pharmacology
Head-to-head clinical analysis: GRANIX versus RELEUKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRANIX versus RELEUKO.
GRANIX vs RELEUKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Granix (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog that binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
Recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation, differentiation, and activation of neutrophil progenitor cells.
5 μg/kg subcutaneously once daily for up to 7 days, or 5 μg/kg subcutaneously once daily for up to 14 days for stem cell mobilization.
5 mcg/kg subcutaneously once daily for up to 10 days or until neutrophil count >10,000/mcL after nadir.
None Documented
None Documented
Terminal half-life approximately 3.5 hours (range 1.8–5.4 h) in healthy subjects; clearance increases with neutrophil recovery due to G-CSF receptor-mediated uptake.
Terminal half-life approximately 5.3 hours (range 4.5–6.2 hours) in adults with normal renal function.
Primarily renal excretion; neutrophil-mediated clearance. <1% unchanged in urine.
Primarily renal (approximately 70% as intact drug). Minor biliary/fecal elimination (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor